RxDoctor Payments Data

Aldine Chandler, MD

Hospitalist · Tucson, AZNPI 1699040709

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,741in general payments, 2019–2025

Across 166 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$276
  • AstraZeneca$224
  • Boehringer Ingelheim$216
  • GSK$216
  • Amgen$204
  • Novo Nordisk$142
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$2,728100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,741 in reported general payments places this provider in the 95th percentile of 578 hospitalist providers in Arizona.

See all hospitalist providers in Arizona

Medicare billing

Part B allowed, 2024
$53,802
Medicare patients
131
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$71,212
GemtesaVibegron34$30,900
JardianceEmpagliflozin14$21,610
OzempicSemaglutide12$10,807
JanuviaSitagliptin Phosphate13$10,469
Breo ElliptaFluticasone/Vilanterol12$7,177
Advair HfaFluticasone Propion/Salmeterol12$4,430
Estradiol51$3,177
Methenamine Hippurate13$2,046
Rosuvastatin Calcium116$2,002
Levothyroxine Sodium132$1,884
Azelastine-FluticasoneAzelastine/Fluticasone15$1,530
Gabapentin102$1,500
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$1,169
Esomeprazole Magnesium27$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$71,21269 claims
Boehringer IngelheimJardiance$216$21,61014 claims
Novo NordiskOzempic$142$10,80712 claims
MerckJanuvia$84$10,46913 claims
GSKBreo Ellipta$216$7,17712 claims
AbbVieSynthroid$276$53914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 hospitalist providers in Arizona.

Other hospitalist in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →